Video: Building a Globally Aligned Post-Market Surveillance System | Duration: 2916s | Summary: Building a Globally Aligned Post-Market Surveillance System | Chapters: Introduction and Welcome (72.085s), NSF Overview and Services (192.555s), Agenda and Overview (316.42s), PMS System Basics (402.865s), PMS Documentation Evaluation (817.56s), UK PMS Requirements (1195.14s), FDA's PMS Approach (1401.21s), Canada's PMS Approach (1594.185s), Global PMS Comparison (1798.605s), Structural PMS Gaps (2070.845s), Strengthening PMS Strategies (2384.015s), Final Takeaway Message (2636.48s), NSF PMS Support (2712.88s), Closing and Resources (2795.55s)
Transcript for "Building a Globally Aligned Post-Market Surveillance System":
Okay, let's start. Good morning and good everyone, wherever you are joining us from today. Thank you so much for taking the time to join this session. I'm really glad to be here with you and to share this keynote today. And before we begin, just a few organizational notes. If you have any questions about today's topic or if anything becomes unclear during the session, please feel free to send me your questions by email. My colleague provided you with the email address in the chat window on the right side, and I will get back to you as soon as possible. So let's get started. Before we dive in, let me briefly introduce myself. My name is Diana Altrage, and I'm a senior consultant for medical devices at NSF Techva Factory. I've been working in the medical device industry for over eleven years, focusing on regulatory affairs, quality management, and especially post market surveillance and vigilance. In my role as is I support companies in developing and maintaining technical documentation across all risk classes, implementing compliant PMS processes, and aligning their quality management systems with international standards such as ISO thirteen four eight five. I also regularly advise on MDR requirements and help organizations strengthen interfaces like complaint handling, risk management, CAPA, and regulatory reporting. Before we move on the main topic, I just wanted to give you a short impression on who NSF is for those who do not know. NSF has been founded in 1944. The main mission of NSF, which has hit its headquarter in Ann Arbor in Michigan, is to improve human and planet health. Around the world, we have a team of 3,000 colleagues working in the field of life sciences, food, and drugs, and also food and nutrition. We are split it in different departments, like I already mentioned. MSF Poseystem is a part of the life sciences department based in Hamburg, Germany. NSF Poseystem works in the field of medical devices, supporting manufacturers with quality management and regulatory affairs as well as fetal diagnostics. In addition, as you can see on this slide, we also operate across other key NSF divisions, including food and nutrition, water, life sciences, where we provide a wide range of solutions for clients worldwide. So on this slide, you can see a quick overview of how we support our clients throughout the entire product life cycle. From the very first design idea all the way to post market surveillance. The wheel here highlights the key phases where NSF process team and the wider NSF team step in, like design and development, clinical affairs, technical documentation, manufacturing, regulatory affairs, and, of course, PMS. And the main point I want to emphasize here is we don't just support one specific stage. We really provide end to end support, whether it's getting started with development, preparing the technical file, navigating regulatory submissions, or staying compliant once the device is already on the market. A short disclaimer. This presentation is based on information available at the present time and has been compiled to the best of my knowledge. So alright. Here's the agenda for today's keynote, and we will start with the basics of post market surveillance on the MDR and IVDR. I will explain what is required. Then we will look at how authorities assess the effectiveness of the PMS system. This often shows gaps between what companies thinks, figures enough, and what regulators expect. Next, we will compare PMS requirements in the European Union, in The UK, US, and Canada. The goals are similar, but the practical differences can be challenging. After that, we will review common structural gaps. These issues often lead to nonconformities in many companies. Once we understand the problems, we will move to solutions. I will share some strategies to make PMS planning and execution stronger and more consistent across regions. And finally, I will give you a short takeaway message to close the session. So let's get started. As mentioned, we will start with the basics of post market surveillance under MDR and IVDR. I'd like to set the foundation by looking at what the regulations actually expect from us when it comes to post market surveillance. PMS is not just an administrative task or something we think about only when issues arise. Under the European regulatory framework, plays a central and ongoing role in ensuring the safety and performance of medical devices. Both the MDR and the IVDR explicitly require manufacture manufacturers to establish a systematic and a proactive PMS system as part of their quality management system. So from the very beginning, PMS is intended to be a fully integrated and continuously running process. The goal is to continuously collect, assess, and document real world die data throughout the device's entire life cycle. This includes everything from performance feedback to safety signals, early trends, and emerging risks. All of this information must flow back into clinical evaluation, risk management, and product improvements. These requirements apply across all device classes, but, of course, the expectations increase with the level of the risk. Higher risk devices require more data, more frequent evaluation, and a stronger evident evidence base. And in a sense, PMS is the mechanism that ensures our device remains safe and effective, not just at market entry, but for us for as long as they are available on patients and users. PMS activities are based on a wide range of data sources. Some of these are reactive, such as complaints, service reports, or vigilance cases. Others are proactive, including user surveys, literature literature monitoring, and data from PMCF and PMPF activities. On this slide, I'd like to walk you through the typical data sources and the types of analysis that form the foundation of an effective postmark surveillance system. So let's begin with the reactive data source. These are inputs that originate from issues or feedback coming to the manufacturer. This includes complaints, customer returns, and service or repair reports, vigilance reports reports such as incident or field safety corrective actions also play a key role here. Additionally, manufacturers must consider feedback received from distributors and importers as well. In contrast to this, proactive data sources are those that the manufacturer actively generates to gain insights. Examples include structured user surveys and feedback programs, ongoing literature monitoring, and the broader market analysis for many devices, PMCF or PMPF activities serve as essential proactive tools to confirm safety and performance after market entry. Internal trend analysis, for instance, from manufacturing nonconformities can also reveal early signals long before they escalate into complaints. Now looking at the analysis activities, the goal is not only to gather these data, but to interpret interpret it in a meaningful way. So trend analysis is crucial for detecting early indications of increased risk. Statistical evaluation helps quantify patterns and complaint or performance data. And finally, manufacturers must assess whether any identified issues impact the device's safety or the performance or the overall benefit risk ratio. Together, these reactive and the proactive sources combined with structured analyzers form the backbone of a strong and a compliant PMF system. Now that we've established what PMS is and why the regulations emphasize it so strongly, let's look at where all this collected collected data actually goes and how it contributes to the broader quality management system. PMS outputs directly support several critical processes. First is the risk management according to ISO fourteen nine seven one. The data gathered through through PMS helps us update the risk assessment and confirm that our control measures are effective for identifying new risks that may not have been evident during premarket development. Also, the clinical evaluation. The real world data or the real world performance data either strengthens the existing clinical evidence or shows us where the data needs to be revised, expanded, or even challenged. The third major area is CAPA, the corrective and preventive action. PMS plays a key role in identifying where corrective actions are needed and triggering preventive actions before any before an issue escalates. In other words, PMS is often the earliest warning signal for emerging problems. Third, the labeling and IQ updates. Whenever we see patterns in use user feedback or usability issues, misuses, or unexpected risk, PMS informs revisions to warnings, precautions, and instructions helping ensure that information for users remain accurate and relevant. And finally, the design and development, the real world insights flow back to R and D, supporting continuous improvement of existing devices or development of next generation products. Altogether, PMS ensures a true closed loop feedback system. It connects the real world performance of the device directly to product improvements and regulatory compliance. This loop is exactly what the MDR and the and the IVDR expect. Living learning system where products evolve based on real evidence from the field. Now let's look at the core PMS documentation required under the regulation, like the PMS plan, the PMS report, and the PSUR. Each of these documents fulfills a different regulatory purpose, and together, they form the backbone of compliant post market activities. The PMS plan is essentially the strategy document. It defines how manufacturers will carry out post market surveillance. This includes the data sources, collection and evaluation, and the responsibilities within the organization. The PMS plan must be fully aligned with the risk management process, the clinical evaluation process, and where applicable with the PMCF activities. So it's not an isolated document. It has to be consistent and interconnected with the rest of the technical documentation. For lower risk devices, manufacturers prepare PMS report. This applies to class one devices under the MDR or class a and b devices under the IVDR. The PMS report is essentially a summary. It compiles PMS data and regular intervals and must be made available to authorities upon request. It reflects the ongoing monitoring, but without the elevated level of analyzers required for higher risk devices. For those devices, the regulations require periodic safety update report, so called PSUR. This applies to class class two a, two b, and three under the MDR and two class c and d under the IVDR. The PSURs are far more structured and analytical document. It includes a benefit risk assessment, a trend analysis, conclusions from PMS and PMCF, and an evaluation of whether the device continues to perform as attended and remains safe for use. Depending on the device class, the PSUR must either be submitted to the notified body or uploaded to Udemyd when required. Together, these documents ensure that PMS activities are not only carried out, but also transparently documented and continuously assessed, making them a key link between real world use, clinical evidence, and regulatory compliance. Now that we've covered the core PMS documents and processes, let's look at how authorities and notified bodies actually evaluate whether a manufacturer's PMS system is effective or not. Under both the MDR and the IVDR regulators expect a PMS system. That is, as we already mentioned, active, data driven, and continuously maintained. One of the first things authorities look at is whether the manufacturer keeps all PMS documentation fully up to date, the PMS plan, the PMS report, or the PSUR, and, of course, where applicable, the PMCF and the PMPS documentation. If these documents are outdated or, let's say, inconsistent with each other, it's often the first indication for the regulators that the PMS system is not functioning properly. Regulators also expect evidence that PMS activities are carried out continuously. This means that surveillance cannot be limited to an annual review before the PSURs due. There must be an ongoing process of collecting and assessing and reacting to data throughout the entire year. Under the MDR and IVDR, PMS cannot rely only on complaints or incident reports or any other reactive data. Manufacturers must also use proactive data like literature reviews, as I mentioned, PMCF, PMPF, or user feedbacks, screen registries, and market intelligence to identify emerging risks early. Authorities also verify compliance with military trends reporting under article 88 of the AMDR. This requires manufacturers to report statistically significant increases in the frequency or severity of non serious incidents or expected undesirable side effects. Trend reporting is often overlooked, but it's a key indicator of regulatory maturity. A functioning PMS system must feed directly back into the quality management system. Regulators expect to see updates to risk management, clinical evaluation, updates to the CAPA process, and the technical file. If PMS findings do not result in any changes over time, this also could raise questions about the effectiveness of the system. Finally, authorities assess the internal traceability of the PMS process. They expect a clear line from the initial signal to the assessment, actions taken, and ultimately to updates in the documentation. This closed loop traceability is essential, and it must be visible, structured, and well documented for the evaluators or regulators. In short, PMS effectiveness is judged not by the quantity of documents, but by how well PMS insights drive drive in continuous improvement and ensure the ongoing safety and performance of the device. After looking at the expectations within the European Union, let's now shift to The United Kingdom and how the MHRA evaluates PMS effectiveness under the new UK regulator regulatory framework. While the principles are broadly aligned with the European Union, the MHRA places a strong emphasis on local formats, continuous surveillance, and the real world evidence. Firstly, the MHR checks whether manufacturers use The UK specific templates and structures defined under the statutory instrument. This includes the PMS plan, the PMS report, and the PSUR. Even if the manufacturer is already compliant with MDR or IVDR documentation, the MHRA expects alignment with The UK formats for device placed on the Great Britain market. A unique point in The UK framework is to emphasize on real world evidence and user experience data. The MHI specifically highlights the importance of capturing real usage patterns, visibility concerns, and post market insights from health care professionals and end users. This reflects The UK's broader push toward evidence based regulation. The UK regulation also defines a specific concept of a continuous PMS period. This means PMS activities must be ongoing throughout the entire life cycle of the device and not performed only in preparation for an annual report or or audit. Manufacturers must be able to demonstrate this continuity in their documentation and internal processes. MHRA also plays a strong focus on vigilance performance, meeting reporting deadlines, threat monitoring requirements, and ensuring that nonserious incidents are tracked and escalated appropriately. Any delay delays or inconsistencies in vigilance reporting are taken as indicators of an ineffective PMS system. Just as in the European Union, PMS in The UK must be closely integrated into the quality management system. Regulators expect clear links between PMS findings and updates to risk management files, also couple workflows and technical documentations. If PMS operates as a solo, it will not meet MHR expectations. Another important aspect is regulatory alignment across The UK. Great Britain follows The UK medical device rules with while Northern Ireland continues to follow the European Union MDR and IVDR under the Windsor framework. Manufacturers must therefore maintain clear alignment and avoid contradictions between UK and European Union PMS documentation when marketing across both regions. Overall, the MHRA expects a PMS system that is locally compliant, continuously active, and strongly grounded in real world evidence with seamless integration to the manufacturers, QMS. After looking at the European Union and The UK, let's turn to The United States. The FDA takes a fundamentally different approach to post market surveillance. Unlike the European Union, which places strong emphasis on PMS plan, sewer, and structured documentation, the FDA assesses PMS effectiveness primarily through vigilance performance and through how well PMS is integrated into the quality system. One of the most important indicators the FDA looks at is the quality and timelines of medical device reports. Manufacturers must submit MDRs promptly and with complete accurate information. Any delays or in are viewed as signs of a weak surveillance system. FDA the FDA also closely evaluates how manufacturers manage correction correction and recalls Under 21 CFR 806, companies must assess field actions properly, document them transparently, and notify FDA when required. Effective recall management is considered a core part of post market surveillance in The US. For certain devices, especially higher risk or novel technologies, FDA may require post approval studies or for five twenty two post market surveillance studies. Compliance with these studies, completing them on time following the protocol and reporting results, is a major indicator of PMS effectiveness. Under the new quality management system regulation, the QMSR, which aligns FDA's quality management system requirements with the ISO thirteen thousand four and eighty five, manufacturers must perform trend analysis and identify early signals proactively. The FDA wants to see that companies do not wait for incidents to escalate before acting. Just like in the European Union and The UK, PMS cannot stand alone. The FDA evaluates how well post market data flows into CAPPA processes, design controls, and risk management. If post market findings are not driving changes, this is a clear red flag for inspectors. And finally, the FDA looks very closely at how quickly and how effectively a manufacturer responds to new safety or performance concerns. This includes internal escalation processes, communication with the FDA, and implementation of corrective actions. Responsiveness is often the strongest indicator of major and effective PMS system. The FDA also closely evaluates how manufacturers manage correct corrections and recalls under Yeah. I already sent it. And now next, let's move to Canada. Health Canada follows a structured but pragmatic approach to post market surveillance. While the framework is less prescriptive than the European model, the expectation for vigilance performance and trend monitoring are very clear, especially for higher risk devices. The first thing Health Canada evaluates is whether manufacturers submit mandatory problem reports within the required timelines, and the reports are central are central pillar of the Canadian vigilance system. Delays or incomplete submissions immediately raise concerns about the effectiveness of the PMS. For class two, three, and four devices, manufacturers must prepare annual summary reports. These reports are expected to contain clear trend evaluations, summarize of post market findings, and the manufacturer's assessment of whether the device continues to perform safely. Even though the format is not strictly regulated, the quality of the content is closely carefully examined examined. Health Canada expects many expects manufacturers to conduct meaningful internal trend analysis regardless of the reporting structure. This includes identifying increases in incident frequency or severity and documenting how those trends were investigated and addressed internally. A lack of trend analysis signals, a weak PMS system. Another major component of the management of recalls and field safety actions, the Health Canada checks whether manufacturers follow the Canadian recall guidance, classify recalls correctly, and communicate clearly with distributors and end users. Effective recall management is considered essential for PMS maturity. Just like in other major markets, PMS is expected to be tightly integrated into the quality management system, and manufacturers must demonstrate that PMS findings are used to update the risk management files, technical documentation, and the cover processes. If PMS outcomes are not triggering improvement, this is also a clear red flag. And finally, Health Canada evaluates whether the manufacturer escalates safety signals promptly and report reports consistently across different regulatory markets. If an issue is reported quickly in The European Union or The US but delayed in Canada, this inconsistency is viewed as a sign of ineffective global PMS coordination. In summary, Health Canada focuses strongly on vigilance performance, on monitoring, and the manufacturers' ability to turn post market data into real quality system actions. So let's bring everything together. Across all major regions, the European Union, The UK, US, and Canada, regulators expect PMS to be to operate as a continuous QMS embedded system. And your reviews are no longer enough. A PMS must function as a living, ongoing process. This requires a clear PMS plan, defined responsibilities, and strong alignment with risk management, clinical evaluation, and the cover process. This means that PMS cannot sit outside DQMS. It must be fully integrated into every major quality process. Regulators also expect balanced data collection from both reactive and sources and proactive activities, like already mentioned, the literature reviews, PMCF activities, registries, and market surveillance. The key question is always, can this system detect early signals and trends? But collecting data is only the beginning. Authorities want to see that PMS findings lead to real actions, trend based escalations, risk and labeling updates, CAPAs, and design improvements, all with a clear traceability from a signal to documentation updates. PMS effectiveness is judged through regulatory compliance across global markets. Timely and consistent reporting, whether in the European Union, in The UK, US, or in Canada, must be lead to aligned updates across all regions. In short, an effective PMS system is defined not by documents, but by how well it uses real world evidence to drive meaningful actions and maintain global regulatory coherence. So with that in mind, let's shift our focus to a broader view, because even though all these regions work toward the same goal, patient safety, the expectations from PMS can be very different. On the next slide, we will look at the key differences between the European Union, The UK, The US, and Canada. In the European Union, we have the most structured and formalized PMS system. That means manufacturers need a PMS plan, a regular PMS report, and depending on the device risk class, a PSUR as well. PMS is really treated as a proactive and an an an and an essential part of the QMS. The UK follows a similar approach, but they use their own UK specific templates. And an important point is the in UPMS framework came into force in June 2025. Also, keep in mind, Great Britain follows UK rules, while Northern Ireland continues to align with the European MDR and IBD. In The US, things work quite differently. There's no requirement for a PMS plan or for a PSUR. Instead, the FDA evaluates PMS mainly through vigilance activities. So MDR reporting recalls post approval studies and 522 studies. Trend analysis is expected under the new q QMSR alignment, but it isn't organized in a formal structured PMS documentation like in the European Union. In Canada, manufacturers are required to perform military problem reporting, handle records, prepare annual summary reports for class two and to four devices. There's no formal PMS plan or PSUR, but regulators do expect companies to perform internal trend analysis. So overall, while the European Union and The UK rely on structured PMS documentation, The US and Canada place more emphasis on vigilance performance and internal trend monitoring. Now that we've looked at how different regions approach PMS, let's move to the something that affects manufacturers everywhere regardless of where they operate. Across all markets, we see the same types of issues coming up again and again, not because companies don't want to comply, but because certain structural gaps are built into their systems and processes. On the next slide, I'd like to walk you through the most common gaps that often lead to nonconformities and why they appear so consistently across the industry. On this slide, I want to highlight some of the structural gaps that we see very often during assessments and that frequently lead to nonconformities. These issues are not unique to one region. We see them across the European Union. We see them in The UK, US, and, of course, also in Canada. So let's start with the first one. It's the foundational PMS and data collection gaps. Many manufacturers struggles with very basic elements, unclear data sources, undefined methods, or missing justification for KPIs and thresholds. When the foundation is weak, the whole PMS system becomes unstable. The next common gap is a lack of comprehensive PMS plan. Plan if the strategy is missing or responsibilities responsibilities are not clearly defined, it becomes almost impossible to measure performance or identify signals early. A third issue is a weak integration with risk management under ISO fourteen nine seven one. PMS data is often not fed back into update risk assessments or control measures, and regulators immediately flag that because risk management should be a living process as defined in the ISO standard. There's also often a sufficient linkage to clinical evaluation and PMCF. PMS outputs might not inform the c inform CER updates, or PMCF activities may be missing or not justified. This is one of the biggest reasons for major findings under the MDR. And finally, inadequate adequate data collection processes. This includes poor complaint capture, incomplete field data, or limited proactive sources like literature, surveys, or broader market feedback. All those all these gaps have one thing in common that prevent the PMS system from giving you a reliable picture of real world device performance, and that's exactly what regulators look for. Let's continue with the second set of structural gaps. These are the ones we see when it comes to analysis, to documentation, and system integration. And these issues very often lead directly to measurable conformities. The first gap is a lack of robust analysis and trending. Manufacturer many manufacturers collect data, but they don't evaluate it properly. There's no trend analysis, no statistical method, and as a result, early signals stay undetected. If KPI and thresholds are not defined, meaningful trend detection simply cannot happen. Another frequent issue is a noncompliant PMS documentation. We often see p m PMS reports or PSURs that are incomplete, outdated, or even inconsistent. Sometimes they don't match the regulatory expectations or they don't reflect the actual device performance. This is one of the most common findings, especially under the MDR. A third gap is a weak cross functional and QMS integration. PMS insights are not reaching design and development. They are not reaching the cover process. They are not reaching the quality or the regulatory affairs. When teams are not connected, signals don't lead to corrective actions and regulator the and regulatory risk increases quickly. And finally, there are global misalignment challenges. Different regions have different reporting timelines and documentation requirements. If these differences aren't addressed on the PMS system, it leads to inconsistencies, audit findings, and compliance failures. Together, these gaps show that the problem is rarely a signal missing document. Say it's single missing document. It's usually missing structure, weak analysis, and pure poor integration across the system. So after looking at the most common structural gaps and why they lead to nonconformities, the natural next question is, of course, what can we actually do about it? Because identifying weakness is only the first step. What really matters is how we translate these insights into stronger processes and then to a and a more reliable PMS system, one that works across regions and supports global compliance. On the next slide, I'd like to walk you through practical strategies that help strengthen both the PMS planning and the PMS execution. These are approaches we see working well across the industry industry and that regulators consistently expect to see. So let's have a look at what can make a real difference. There are a few practical strategies that make a real difference, and regulators expect to see them. So let's start with the foundation, developing developing comprehensive PMS plans. This means defining clear objectives, data sources, KPIs, thresholds, and the rationale behind them. A strong PMS plan is aligned with risk management with clinical evaluation and PMCF, and it also includes region specific reporting and documentation requirements. The next strategy is to improve data collection and proactive surveillance. Here, goal is to combine reactive data like complaints with proactive sources such as surveys, literature, and market intelligence. Standardizing methods for collecting and validating field data is essential. And for global companies, ensuring consistency across regions is critical, especially when it comes to data formats and classification. And finally, we can leverage digital tools for analysis. Automate automation can support complaint training and statistical statistical evaluations, and dashboards allow real time monitoring of safety signals. And centralized data systems help companies make faster and more informed decisions. These strategies create a PMS system that is more proactive, more reliable, and more globally aligned, which is exactly what regulators are looking for. Let's continue with a few more strategies that help make PMS process stronger and more reliable, especially when it comes to integration and accountability. One important area is cross functional integration and alignment with the QMS. As I already mentioned, PMS cannot work in isolation, so linking PMS outputs to capital risk management and design controls is essential. Structured cross function review meetings also help teams stay aligned and having clear escalation rules ensures that emerging risk are handled quickly and consistently. Another key element is a strong governance, clear rules, and proper training. Teams need explicit responsibilities and ownership for PMS activities. Regular training on PMS requirements, signal detection, and documentations then let's help keep everyone up to date. And focused internal audits are a great way to verify whether the system is actually working as intended. And finally, a global alignment and and compliance are becoming more important than ever. This means mapping regulatory requirements across all markets using harmonized templates with room for regional differences and keeping a global PMS compliance calendar to avoid missed obligations. These altogether, these practice helps create a PMS system that is consistent, transparent, and fully integrated into the broader quality system no matter where company operates. Alright. We are almost at the end of today's session. So before we wrap up, I want to leave you with one final takeaway message. We've talked through a lot of aspects of PMS from global differences to common structural gaps and practical strategies. On this slide, I've summarized the most important points for you. One of the biggest success factors is cross functional integration. So that means making sure PMS outputs actual reach kappa risk management and design controls. People need to know exactly what they are responsible for. And finally, we have the topic of the global alignment. This is something many companies struggle with. Different regions have different requirements, and if you don't actively map those out, you quick quickly get inconsistencies. Harmonized templates can help a lot, and the global PMS compliance calendar is a simple is a simple but effective way to avoid miss missed deadlines. So if there's one thing to take away from today is that the proactive, well integrated PMS system doesn't just help you meet the rules, it helps you build safer and more reliable medical device. So before we close, I'd like to give you a quick overview of how we at NSF support companies in strengthening their PMS system, especially when it comes to putting all these strategies into practice. Many of the challenges we discussed today are not about willingness, but about capacity and clarity, and that's exactly where we can help. And we support manufacturers in developing and maintaining PMS tools that are aligned with international expectations. We have create structured PMS processes and templates. We also support complaint complaint handling and reporting by providing process templates that meet international obligations. Another area many companies struggle with is trend analysis, so we help establish methods that fit both regulatory expectation and the ISO fourteen nine seven one. And for teams that need support in day to day PMS work, we assist with evaluating post market data sources and preparing PMS reports. And, of course, if teams need more hands on knowledge, we offer seminars on-site training sessions to build internal competence So whether it's designed towards building processes or supporting the actual execution, we help companies turn PMS requirements into a system that really works. So thank you very much for your time and attention today. I truly truly appreciate you joining the session, and I hope the insights we discussed will support you in strengthening your PMS system and global compliance efforts. It was a pleasure speaking with you, and I look forward to staying connected. Before I close this session, I want to just give you a quick reminder about the services we offer, whether it's it is consultancy support, tech purfatory services, or clinical services. If you're interested in learning more, you will find a QR code on the slide deck you will receive after this session. Simply scan it, and you will get direct access to additional information and contact options. And just one more quick update about our upcoming keynotes in February and March. If you'd like more information about the next session, simply scan also the QR code shown here. You will find all the details about the upcoming keynotes if you are interested in. And before we officially close, here are the easiest way to get in touch with us. If you'd like to follow-up or learn more, you can visit our website for detailed information on all our services and resources. If you prefer staying connected through social media, feel free to follow us on LinkedIn. And, of course, you can always reach out to us directly by email or phone if you have questions or need support. We are always happy to help and look forward to connecting with you. And, again, thank you very much for your time and attention today. Have a good day or evening. Thank you.